Name:
Cetirizine to-li for oral administration 10mgml per vial 20ml per pack No. 1
Description:
Colorless transparent liquid without sediment, with a slight characteristic smell of acetic acid. The main active substance Cetirizine Form of releaseDrops Dosage 10 mg / 1 ml 20 ml Pharmacological properties CETIRIZINE-FT belongs to peripheral Hi-receptor blockers, eliminates the effect of histamine released in the body during allergic reactions and has a pronounced anti-allergic effect. It has antipruritic and anti-edematous effect. Indications for use For adults and children 6 years of age and older: treatment of seasonal and year-round allergic rhinitis (the duration of treatment in children with seasonal allergic rhinitis is a maximum of 4 weeks); treatment of allergic conjunctivitis; treatment of chronic idiopathic urticaria. For children aged 2 to 6 years: treatment of seasonal allergic rhinitis. For children aged 6 months to 2 years: treatment of perennial allergic rhinitis; treatment of chronic idiopathic urticaria. Dosage and administration CETIRIZINE-FT is administered orally, regardless of food intake. The drug can be taken undiluted or diluted in a glass of water. It is preferable to take the drug in the evening, because. at this time of day, the symptoms are more pronounced. Seasonal allergic rhinitis Adults and adolescents over 12 years of age: the recommended dose of the drug is 10 mg of cetirizine dihydrochloride (24 drops) once a day. Children aged 6 to 12 years: The recommended dose is 10 mg cetirizine dihydrochloride (24 drops) once daily for up to 4 weeks. The dose can be divided into two doses (12 drops in the morning and evening). Children aged 2 to 6 years: The recommended daily dose is 5 mg cetirizine dihydrochloride (12 drops) in two doses (6 drops in the morning and evening). The duration of treatment is not more than 4 weeks. Allergic conjunctivitis Adults and adolescents over 12 years of age: the recommended dose of the drug is 10 mg of cetirizine dihydrochloride (24 drops) once a day. Children aged 6 to 12 years: 10 mg cetirizine dihydrochloride (24 drops) once daily for up to 4 weeks. The dose can be divided into two doses (12 drops in the morning and evening). Perennial allergic rhinitis, chronic idiopathic urticaria Adults and adolescents over 12 years of age: the recommended dose of the drug is 10 mg of cetirizine dihydrochloride (24 drops) once a day. Children aged 6 to 12 years: The recommended dose is 10 mg cetirizine dihydrochloride (24 drops) once a day. The daily dose can be divided into two doses (12 drops in the morning and evening). For children aged 6 months to 2 years, the drug is prescribed only on the recommendation of a doctor. Special patient groups Elderly: with normal renal function, there is no need to reduce the dose of CETIRIZINE-FT. In case of impaired renal function in elderly patients, the dose should be adjusted. Patients with impaired renal function: since cetirizine is excreted mainly through the kidneys, the dose of the drug should be selected individually depending on the value of creatinine clearance (CC). CC for men can be calculated by the formula, based on the values of serum creatinine: CC (ml / min) u003d 140 – age (years)? body weight (kg) / 72 ? creatinine concentration (mg / dl) For women, CC is calculated by multiplying the obtained value by a factor of 0.85. For children with renal insufficiency, the dose is selected individually, taking into account CC and body weight. Patients with impaired liver function alone do not need to adjust the dose. Patients with impaired liver and kidney function require individual dose selection (see table above). If mild side effects occur in adults and adolescents over 12 years of age, it is recommended to take 12 drops of CETIRIZINE-FT in the morning and evening. The duration of treatment is determined by the doctor individually, depending on the course of the disease. The maximum duration of treatment for seasonal allergic rhinitis in children from 2 to 12 years old and allergic conjunctivitis in children from 6 to 12 years old is 4 weeks. If you forget to take CETIRIZINE-FT, do not take a double dose to make up for the missed dose. Skip the missed dose and continue taking the drug as usual. Use during pregnancy and lactation Pregnancy In the first trimester of pregnancy, CETIRIZINE-FT is not recommended. The decision to prescribe the drug in the second and third trimester is taken only by the doctor after a thorough assessment of the ratio of the expected benefit to the mother and the risk to the fetus. If possible, a safer drug should be used. Lactation Cetirizine passes into breast milk, so it is recommended to interrupt breastfeeding during treatment with CETIRIZINE-FT. Precautions In patients with impaired renal function, the dose of CETIRIZINE-FT should be selected individually (see section “Method of administration and doses”). In elderly patients, due to a possible decrease in renal function, the dose of the drug should be adjusted. In patients with epilepsy and a tendency to convulsions, the use of CETIRIZINE-FT should be carried out with caution. In the treatment of the drug should avoid drinking alcohol and taking drugs that depress the central nervous system. Care should be taken when prescribing to patients with problems with urination (benign prostatic hyperplasia, spinal cord injury, etc.), because. cetirizine may increase the risk of urinary retention. Methyl parahydroxybenzoate and propyl parahydroxybenzoate contained in CETIRIZINE-FT may cause allergic reactions. Use in children Due to the lack of relevant studies, the use of cetirizine in children under 6 months of age is not recommended. Influence on the ability to drive vehicles and other complex mechanisms In some cases, cetirizine may cause drowsiness. Therefore, after taking CETIRIZINE-FT, you cannot drive vehicles and perform other potentially hazardous activities that require increased concentration of attention and speed of psychomotor reactions. Interaction with other drugs With the simultaneous use of cetirizine with pseudoephedrine, cimetidine, ketoconazole, erythromycin, azithromycin, theophylline, diazepam, gipizide, no clinically significant pharmacodynamic and pharmacokinetic interactions were observed. When combined with ketoconazole, macrolides, theophylline and pseudoephedrine, no changes in the ECG were detected. When using the drug in therapeutic doses, no data were obtained on a significant increase in the effect of alcohol. According to in vitro studies, cetirizine does not change the binding of warfarin to blood proteins. With simultaneous course treatment with ritonavir (600 mg 2 times a day), the duration of action of cetirizine at a dose of 10 mg / day increases by 40%, the effect of ritonavir decreases by 11%. When combining cetirizine at a dose of 20 mg/day with theophylline 400 mg/day, an increase in the AUC24 value of cetirizine by 19%, theophylline by 11% was revealed; Cmax of cetirizine increased by 7.7%, theophylline by 6.4%. In the event that theophylline was first prescribed, and then cetirizine was added, the clearance of cetirizine decreased by 16%, and the clearance of theophylline by 10%. However, in individuals initially treated with cetirizine, the addition of theophylline did not lead to a change in the pharmacokinetics of the latter. After a single dose of 10 mg of cetirizine, the effect of alcohol does not increase significantly (0.8% o). When co-administered with diazepam 5 mg, a clinically significant interaction was observed in only one of 16 psychometric tests. Co-administration of 10 mg cetirizine with glipizide may slightly lower blood glucose levels. When taking cetirizine daily with glipizide, it is recommended to take glipizide in the morning and cetirizine in the evening. The degree of absorption of cetirizine does not decrease when taken together with food, although the absorption rate decreases by 1 hour. Cetirizine should be discontinued at least three days before skin allergy testing. Contraindications hypersensitivity to cetirizine, hydroxyzine or any piperazine derivative, as well as to any of the auxiliary components of the drug; terminal stage of renal failure (CC < 10 ml / min). Composition Active substance: cetirizine dihydrochloride 10 mg/ml Excipients: propylene glycol, glycerin, sodium acetate trihydrate, sodium saccharin, methyl parahydroxybenzoate, glacial acetic acid, propyl parahydroxybenzoate, purified water. Overdose Symptoms of an overdose of CETIRIZINE-FT are usually related to its CNS effects and anticholinergic activity. Taking cetirizine at a dose 5 times the recommended daily dose is accompanied by symptoms such as confusion, diarrhea, dizziness, fatigue, headache, malaise, mydriasis, itching, anxiety, sedation, drowsiness, stupor, tachycardia, tremor and urinary retention. Treatment. Within an hour after an overdose, it is necessary to wash the stomach, give activated charcoal. If necessary, symptomatic and supportive therapy is recommended. There is no specific antidote. Hemodialysis with an overdose of cetirizine is not effective. Side effects Clinical studies have shown that at the recommended dosages, cetirizine causes minor adverse reactions from the central nervous system, including drowsiness, fatigue, dizziness and headache. In some cases, paradoxical stimulation of the central nervous system has been noted. Although cetirizine is a selective peripheral H1 receptor antagonist and has little or no anticholinergic activity, urinary difficulties, accommodation disorders and dry mouth have been reported in isolated cases. There have been cases of abnormal liver function with an increase in the level of liver enzymes, accompanied by an increased level of bilirubin. Basically, these changes disappear when treatment with cetirizine dihydrochloride is discontinued. Adverse reactions are indicated by body systems and frequency of occurrence, as: very often (? 1/10); often (from? 1/100 to <1/10); infrequently (from? 1/1000 to < 1/100); rarely (from? 1/10000 to <1/1000); very rarely (< 1/10000), the frequency is unknown (it is impossible to determine the frequency from the available data). From the side of the cardiovascular system: rarely - tachycardia. On the part of the blood and lymphatic system: very rarely - thrombocytopenia. From the nervous system: infrequently - paresthesia; rarely - convulsions, movement disorders; very rarely - taste perversion, fainting, tremor, dyskinesia, dystonia; frequency unknown - deafness, amnesia, memory impairment. On the part of the organ of vision: very rarely - a violation of accommodation, blurred vision, oculogyric crisis; frequency unknown - vasculitis. On the part of the organ of hearing and labyrinth disorders: the frequency is unknown - dizziness. From the gastrointestinal tract: infrequently - diarrhea. From the side of the kidneys and urinary system: very rarely - dysuria, enuresis; frequency unknown - urinary retention. From the skin and subcutaneous tissue: infrequently - itching, rash; rarely - urticaria; very rarely - angioedema, fixed erythema. General disorders and disorders at the injection site: infrequently - asthenia, malaise; rarely - edema, weight gain. From the immune system: rarely - hypersensitivity; very rarely - anaphylactic shock. From the hepatobiliary system: rarely - an increase in the activity of transaminases, alkaline phosphatase, β-HT and bilirubin. From the side of metabolism and nutrition: the frequency is unknown - increased appetite. On the part of the psyche: infrequently - arousal; rarely - aggression, confusion, depression, insomnia, hallucinations; very rarely - tick; frequency unknown - suicidal thoughts. If the listed adverse reactions occur, as well as a reaction not listed in the package leaflet, it is necessary to inform the attending physician. Storage conditionsKeep in a place protected from light at a temperature not exceeding 25°C. Keep out of the reach of children! Buy Cetirizine drops for oral administration 10mg/ml 20ml No. 1
Cetirizine drops for oral administration 10mg/ml 20ml №1
$20.00
SKU: 123453
Category: Allergy medicines
INN | CETIRIZINE |
---|---|
The code | 123 453 |
Barcode | 4 810 201 018 973 |
Dosage | 10mg/ml |
Active substance | cetirizine |
Manufacturer | Borisovsky ZMP, Belarus |
Reviews
There are no reviews yet.